Overview

Anlotinib in Advanced Solid Tumors With FGFR Alteration

Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This clinical trial aims to evaluate the efficacy, safety of Anlotinib in advanced solid tumors with FGFR alteration.
Phase:
N/A
Details
Lead Sponsor:
Shanghai Changzheng Hospital